{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:35:55Z","timestamp":1786772155912,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,24]]},"DOI":"10.7759\/cureus.111434","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:49:08Z","timestamp":1782316148000},"source":"Crossref","is-referenced-by-count":1,"title":["Fatal Acute Liver Failure Associated With Presumed Hepatitis B Virus Reactivation During Rituximab Maintenance Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"James","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asis A","family":"Babun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whinkie","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al-Sarray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali FS","year":"2025","unstructured":"Ali FS, Nguyen MH, Hernaez R, et al.. AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals. Gastroenterology. 2025, 168:267-84. 10.1053\/j.gastro.2024.11.008","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16725","article-title":"Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B","volume":"39","author":"Hou KC","year":"2024","unstructured":"Hou KC, Su TH, Kao CN, et al.. Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B. J Gastroenterol Hepatol. 2024, 39:2447-55. 10.1111\/jgh.16725","journal-title":"J Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i26.3299","article-title":"Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention","volume":"25","author":"Sagnelli C","year":"2019","unstructured":"Sagnelli C, Pisaturo M, Cal\u00f2 F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol. 2019, 25:3299-312. 10.3748\/wjg.v25.i26.3299","journal-title":"World J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault NA","year":"2018","unstructured":"Terrault NA, Lok AS, McMahon BJ, et al.. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018, 67:1560-99. 10.1002\/hep.29800","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang JP","year":"2020","unstructured":"Hwang JP, Feld JJ, Hammond SP, et al.. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020, 38:3698-715. 10.1200\/JCO.20.01757","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00118-3","article-title":"Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)","volume":"16","author":"Mallet V","year":"2016","unstructured":"Mallet V, van B\u00f6mmel F, Doerig C, et al.. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016, 16:606-17. 10.1016\/S1473-3099(16)00118-3","journal-title":"Lancet Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy KR","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015, 148:215-9. 10.1053\/j.gastro.2014.10.039","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043672","article-title":"Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab","volume":"10","author":"Haider M","year":"2020","unstructured":"Haider M, Flocco G, Lopez R, Carey W. Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab. BMJ Open. 2020, 10:e043672. 10.1136\/bmjopen-2020-043672","journal-title":"BMJ Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto WK","year":"2014","unstructured":"Seto WK, Chan TS, Hwang YY, et al.. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014, 32:3736-43. 10.1200\/JCO.2014.56.7081","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i33.4942","article-title":"Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era","volume":"29","author":"Mak JW","year":"2023","unstructured":"Mak JW, Law AW, Law KW, Ho R, Cheung CK, Law MF. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastroenterol. 2023, 29:4942-61. 10.3748\/wjg.v29.i33.4942","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix178","article-title":"Characteristics, prevention, and management of hepatitis B virus (HBV) reactivation in HBV-infected patients who require immunosuppressive therapy","volume":"216","author":"Choi J","year":"2017","unstructured":"Choi J, Lim YS. Characteristics, prevention, and management of hepatitis B virus (HBV) reactivation in HBV-infected patients who require immunosuppressive therapy. J Infect Dis. 2017, 216:S778-84. 10.1093\/infdis\/jix178","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling M","year":"2021","unstructured":"Dreyling M, Ghielmini M, Rule S, et al.. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021, 32:298-308. 10.1016\/j.annonc.2020.11.008","journal-title":"Ann Oncol"},{"key":"ref13","unstructured":"B-cell lymphomas. (2024). Accessed. 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1063616","article-title":"Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection","volume":"13","author":"Yan Y","year":"2022","unstructured":"Yan Y, Sun H, Chang L, et al.. Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection. Front Microbiol. 2022, 13:1063616. 10.3389\/fmicb.2022.1063616","journal-title":"Front Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30076-0","article-title":"Significance of anti-HBc alone serological status in clinical practice","volume":"2","author":"Wang Q","year":"2017","unstructured":"Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol. 2017, 2:123-34. 10.1016\/S2468-1253(16)30076-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i39.8720","article-title":"Update on occult hepatitis B virus infection","volume":"22","author":"Makvandi M","year":"2016","unstructured":"Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol. 2016, 22:8720-34. 10.3748\/wjg.v22.i39.8720","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes","volume":"107","author":"Makatsori M","year":"2014","unstructured":"Makatsori M, Kiani-Alikhan S, Manson AL, et al.. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014, 107:821-8. 10.1093\/qjmed\/hcu094","journal-title":"QJM"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/487920-fatal-acute-liver-failure-associated-with-presumed-hepatitis-b-virus-reactivation-during-rituximab-maintenance-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:49:15Z","timestamp":1782316155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/487920-fatal-acute-liver-failure-associated-with-presumed-hepatitis-b-virus-reactivation-during-rituximab-maintenance-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.111434","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}